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A B S T R A C T   
The physiochemical properties of acidic or basic active pharmaceutical ingredients (APIs) can be optimised by 
forming salts with different counterions. The aim of this work was to synthesise a novel salt of propranolol (PRO) 
using sebacic acid (SEBA) as the counterion and to gain mechanistic understanding of not only the salt formation, 
but also its eutectic phase formation with SEBA. Thermal analysis showed a solid-state reaction occurring be-
tween PRO and SEBA leading to the formation of dipropranolol sebacate (DPS) melting at app. 170 ◦C and the 
eutectic composed of DPS and SEBA melting at app. 103 ◦C, comprising 0.33 mol fraction of PRO as determined 
by the Tammann plot. X-ray diffraction and Fourier-transform infrared spectroscopy (FTIR) confirmed the 
identity of the new multicomponent phases of PRO. DPS can be conveniently obtained by heat-induced crys-
tallisation, grinding and conventional solvent crystallisation. Detailed analysis by FTIR revealed H-bond in-
teractions between DPS and SEBA at the inter-phase in the eutectic. Bravais, Friedel, Donnay and Harker crystal 
morphology coupled with full interaction maps analysis allowed to understand further the nature of interactions 
which led to formation of the eutectic phase. This work contributes to furthering research on multicomponent 
pharmaceutical systems to harness their full potential.   
1. Introduction 
Adequate aqueous solubility of orally administrated active pharma-
ceutical ingredients (APIs) is essential to ensure good bioavailability 
(Savjani et al., 2012). Nevertheless, up to 90% of APIs in the develop-
ment stage may be considered as poorly soluble (Ting et al., 2018) and 
thus are more likely to fail during late-stage drug development. There-
fore, the solubility problem should be overcome as early as possible by 
developing more soluble forms of drugs. The search for new forms of 
APIs, which have desirable properties, has become of paramount 
importance to the pharmaceutical industry in recent years. Alternative 
forms of API may include, but are not limited to, polymorphs, salts, 
cocrystals, ionic liquids or eutectics. Since many drugs are either weak 
acids or weak bases, the salt formation is by far the easiest way to 
optimise chemical and physical properties of poorly soluble APIs. The 
salt formation strategy can not only increase API solubility (Serajuddin, 
2007), but it can also be used to improve stability (Sigfridsson et al., 
2018), permeability (Mannava et al., 2020) and well as efficacy and 
release profiles. 
Solvent-free, green synthesis is drawing attention of the pharma-
ceutical industry. Mechanochemistry offers environmentally friendly 
synthesis since no solvent waste is produced and excess of reagents is not 
required. Furthermore, it allows the use of solvent and/or heat sensitive 
reactants and products (Mottillo and Frǐsčić, 2017). In recent years there 
has been an increased amount of accounts published on the mechano-
chemical approach to salt and co-crystal formation (Évora et al., 2019). 
Solid state reactions have also been studied in the context of stability of 
pharmaceutical formulations (Feng and Li, 2005). Solvent-free crystal-
lisation methods include contact formation, solid-state grinding/ball 
milling and heat-induced crystallisation (Karimi-Jafari et al., 2018). 
With ball milling being the well-established method for forming salts 
and co-crystals, hot-melt extrusion, as scalable method of heat-induced 
crystallisation, is becoming a popular technology in salt/co-crystal for-
mation in the solid state (Bookwala et al., 2018). Examples of multi-
component systems synthesised by solvent-free methods include an 
indomethacin/tromethamine salt (Bookwala et al., 2018), lamotrigine 
salts and co-crystals with xanthines and pyridinecarboxamides (Évora 
et al., 2019) and crystalline and amorphous salts of ciprofloxacin 
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(Paluch et al., 2013). 
Propranolol (PRO) is a first-generation nonselective β-blocker 
(Kawanishi et al., 1992). It has traditionally been used in the treatment 
of cardiovascular diseases such as hypertension, cardiac arrhythmias 
and angina pectoris (Andreasen and Andersson, 2018). More recently it 
was introduced as a first-line therapy drug for infantile haemangioma, a 
common benign vascular tumour affecting around 5% of the infantile 
population (Léauté-Labrèze et al., 2017; Wagner et al., 2018). PRO is a 
poorly soluble weak base (609.4 mg/L) (Ferrari et al., 2004), thus it is 
marketed as the hydrochloride salt (PRO⋅HCl), which has solubility of 
97.9 g/L (Thomas and Rubino, 1996). The hydrochloride is the most 
frequently used counterion in the pharmaceutical salt formation. It is 
used in app. 40% of all pharmaceutical salts formed (Paulekuhn et al., 
2007). Despite the significant improvement in the solubility, PRO is 
poorly bioavailable (13–23%). Also, it undergoes extensive hepatic first- 
pass metabolism (Al Shaker et al., 2017). Low bioavailability of PRO can 
lead to a patient receiving an inconsistent dose which impairs achieving 
a therapeutic effect and causes unwanted side effects (Pathak and 
Raghuvanshi, 2015). Over the years, many attempts have been made to 
improve the biopharmaceutical properties of PRO by forming salts with 
counterions other than the hydrochloride. Stepanovs and co-workers 
developed a series of salts, cocrystals and solvates of PRO with oxalic, 
maleic and fumaric acids (Stepanovs et al., 2015). The developed salts, 
due to lower solubility than the PRO⋅HCl form, were considered as 
promising candidates for extended-release formulations. Compared with 
immediate-release tablets, extended-release formulations could 
decrease fluctuations of drug concentration in serum reducing side ef-
fects. Topical administration of PRO has also been explored. It has been 
shown that a salt formed between PRO and capric acid is capable of 
permeation through human skin by an ion-pair mechanism (Stott et al., 
2001). 
The chemical structure of PRO, shown in Fig. 1, comprises a sec-
ondary amine group, which potentially can act as a hydrogen bond 
donor and/or acceptor. Since PRO is a weak base with a pKa of 9.7, a 
possibility of salt and co-crystal formation with an acidic counterion 
should be investigated. In the current study, we have selected sebacic 
acid (SEBA) as a potential beneficial counterion. SEBA is a dicarboxylic 
acid with a carbon chain length of 10. Dicarboxylic acids are used as 
counterions since they are multi-ionisable and phases with different 
stoichiometries may be formed. The carboxylic groups on both ends of 
the acid can act as a hydrogen bond donor, while the amine of PRO can 
act as a hydrogen bond acceptor. The pKa difference between PRO and 
SEBA is greater than 3 (pKa PRO = 9.7, pKa SEBA = 4.7, ΔpKa = 5), 
therefore a salt formation is expected for this system (Childs et al., 
2007). Furthermore, SEBA is a pharmaceutically acceptable acid. It has 
been used to synthesise a range of cocrystals with several APIs such as 
sildenafil (Sanphui et al., 2013), isoniazid (Sarcevica et al., 2013), 
pyrazinamide (Wang et al., 2015) and apatinib (Zhu et al., 2018). PRO 
has been found to have irritative and ulcerogenic effect on oesophagus, 
similar to another β-blocker, alprenolol (Olovson et al., 1983). It has 
been reported that the use of SEBA as counterion to form a salt of 
alprenolol reduced its ulcerogenic and irritative effect (Olovson et al., 
1986). Therefore, the use of SEBA as a counterion in a PRO salt may also 
reduce its ulcerogenic effect. 
The key aim of this study was to develop novel multicomponent 
systems, possibly a salt, of PRO with SEBA. PRO has already shown the 
ability to form a salt and eutectic forms with capric acid, which is a 
monocarboxylic acid with a carbon chain length of 10 (Stott et al., 
1998), thus SEBA is the corresponding dicarboxylic acid. Therefore, the 
work presented here investigates how the inclusion of another carbox-
ylic group in capric acid may change the propensity of PRO to form 
binary systems. We have explored different solvent-free approaches to 
the salt formation. The new solid-state forms composed of PRO and 
SEBA were investigated by detailed thermal analysis studies and con-
struction of phase diagrams, further supported by powder X-ray 
diffraction and infrared spectroscopy to elucidate the usefulness of using 
SEBA as the counterion in PRO binary phases. Finally, computational 
studies were performed to understand intermolecular interactions be-
tween the different forms of PRO leading to the eutectic phase formation 
between the new salt and SEBA. 
2. Materials and methods 
2.1. Materials 
Propranolol hydrochloride (PRO⋅HCl) was obtained from Glentham 
Life Sciences (UK) as a racemic mixture. Sebacic acid (SEBA) was pur-
chased from Sigma Aldrich Chemie GmbH (Germany) and was used as 
supplied. Both chemicals had a purity of at least 99%. Ethanol was ob-
tained from Fisher Scientific (UK) and was of HPLC grade. All other 
chemicals and solvents were of analytical grade. 
2.2. Methods 
2.2.1. Synthesis of propranolol base 
Propranolol base (PRO) was obtained from its hydrochloride form. A 
quantity of 2 g of PRO⋅HCl was dissolved in 100 mL of deionised water. 
A saturated aqueous NaHCO3 solution was added to the PRO⋅HCl solu-
tion until pH of 9 was reached while constantly stirring using a magnetic 
stirrer (Stuart SD162 Hotplate stirrer, UK) at a speed of 1000 rpm. A 
white suspension of PRO was obtained under these conditions, which 
was then filtered under vacuum using a ceramic Buchner flask with a 
0.45 μm polypropylene membrane disc filter. The wet precipitate was 
washed with 50 mL of deionised water to eliminate any remaining 
water-soluble residues and dried at 70 ◦C for 2 h in an oven (Memmert 
UL 40, Germany). 
2.2.2. Synthesis of dipropranolol sebacate salt 
To obtain the dipropranolol sebacate (DPS) salt, PRO and SEBA were 
dissolved in hot ethanol in 1:1 M ratio in a 100 mL beaker. The reaction 
solution was constantly stirred using a magnetic stirrer (Stuart SD162 
Hotplate stirrer, UK) at a speed of 1000 rpm to ensure complete disso-
lution of the components. The solution was then quench cooled by 
placing the beaker in an ice bath and kept at 4 ◦C overnight to allow salt 
Fig. 1. Chemical structures and pKa values of propranolol (PRO) and sebacic acid (SEBA).  
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precipitation. The precipitated salt was filtered under vacuum using a 
ceramic Buchner flask equipped with 0.45 μm polypropylene membrane 
disc filter. The salt was washed with 10 mL of ice-cold ethanol. DPS was 
dried overnight at 60 ◦C (Memmert UL 40, Germany) and its purity was 
confirmed by thermal analysis. The salt was stored in a 20 mL sealed 
amber glass jar at ambient temperature and moisture. 
2.2.3. Preparation of PRO/SEBA and DPS/SEBA physical mixtures 
Approximately 50 mg aliquots of physical mixtures of PRO/SEBA 
and DPS/SEBA were prepared by grinding accurately weighted quanti-
ties of the constituent powders, in appropriate molar ratios, using an 
agate mortar and pestle at room temperature. The molar fraction of PRO 
in the PRO/SEBA physical mixtures varied between 0 and 1. The 
quantity of drug in the DPS/SEBA mixtures is expressed as a molar 
fraction of PRO. 
2.2.4. Preparation of samples for contact and grinding-assisted salt 
formation methods 
PRO and SEBA were first pre-dried in the Memmert UL 40 oven at 
70 ◦C for 1 h. For the contact salt formation method, pre-dried PRO and 
SEBA powders in the 2:1 M ratio were mixed gently in a 20 mL glass vial 
with a spatula. A total quantity of 20 mg mixture was prepared. For the 
grinding-assisted salt formation, 20 mg of the PRO/SEBA 2:1 M ratio 
mix were ground for 5 min in an agate mortar and pestle and then 
transferred to a 20 mL glass vial. All samples were hermetically sealed 
and stored at 25 and 60 ◦C in the oven (Memmert UL 40). 
2.2.5. Preparation of the DPS and SEBA eutectic composition 
20 mg of the eutectic was prepared by grinding SEBA (0.75 mmol) 
and DPS (0.25 mmol) for 5 min in an agate mortar and pestle. The 
sample was stored in a 20 mL sealed amber glass jar at ambient tem-
perature and moisture. 
2.2.6. Differential scanning calorimetry (DSC) 
DSC measurements were carried out using a PerkinElmer Diamond 
DSC unit (USA). The unit was refrigerated using an ULSP B.V. 130 
cooling system (Netherlands). Pyris software 9.01.0174 was used for 
data analysis. The DSC unit was calibrated using an indium standard. A 
heating rate of 10 ◦C/min was used (unless otherwise specified) with 
nitrogen (40 mL/min) as the purge gas. For the flash quenching step, a 
nominal cooling rate of 300 ◦C/min was applied. If required, the 
supercooled samples were re-heated at 10 ◦C/min. Approximately 5–10 
mg samples were analysed in sealed 40 μL aluminium pans. The analysis 
was repeated at least in duplicate (Umerska et al., 2020). 
2.2.7. Thermogravimetric analysis (TGA) 
TGA was carried out using a Mettler Toledo TG50 TGA unit 
(Switzerland). The unit was coupled to a Mettler Toledo MT50 balance 
(Switzerland). Approximately 4 mg samples were analysed in non-sealed 
40 µL aluminium pans. Samples were measured in triplicate by heating 
from 25 to 170 ◦C at a rate of 10 ◦C/min under nitrogen (40 mL/min) as 
a purge gas. 
2.2.8. Powder X-ray diffraction (PXRD) 
PXRD analysis was conducted using a Rigaku MiniFlexII Desktop X- 
ray diffractometer (Japan) with a Haskris cooling unit (USA). The tube 
(Cu, 1 kW normal focus) output voltage used was 30 kV and tube output 
current was 15 mA. Measurements were taken from 5 to 40̊ on the 2theta 
scale at a step size of 0.05̊ per second at room temperature. PRO/SEBA 
samples were analysed “as is” or were heat pre-treated: samples con-
taining 0.1–0.5 mol fraction of PRO were heated to 100 ◦C, cooled to 
room temperature and then analysed by PXRD; samples containing 
0.6–0.9 mol fraction of PRO were heated to 120 ◦C, cooled to room 
temperature and then analysed. 
2.2.9. Solid state Fourier transform infrared spectroscopy (FTIR) 
FTIR was performed using a Spectrum One FT-IR spectrometer 
(PerkinElmer, Connecticut, USA) equipped with Universal ATR Sam-
pling Accessory. The Spectrum Software version 6.1 was used. A spectral 
range of 450–4000 cm− 1 and a resolution of 4 cm− 1 were used. PRO/ 
SEBA samples were analysed “as is” or were heat pre-treated: samples 
containing 0.1–0.5 mol fraction of PRO were heated to 100 ◦C, cooled to 
room temperature and then analysed by PXRD; samples containing 
0.6–0.9 mol fraction of PRO were heated to 120 ◦C, cooled to room 
temperature and then analysed as described above in Section 2.2.8. 
2.2.10. Single crystal X-ray diffraction (SCXRD) 
Single crystals of the salt suitable for structural analysis were grown 
from an ethanolic solution of PRO and SEBA. The components in a 2:1 
ratio (PRO:SEBA) were dissolved in 10 mL of HPLC grade ethanol in a 
glass vial. This solution was left under a fume hood at room temperature 
for solvent evaporation. Data for the sample were collected on a Bruker 
APEX DUO using Cu Kα radiation (λ = 1.54178 Å). The sample was 
mounted on a MiTeGen cryoloop and data collected at 100(2) K using an 
Oxford Cobra cryosystem. Bruker APEX3 software was used to collect 
and reduce data and determine the space group. Absorption corrections 
were applied using Bruker SADABS software. Structures were solved 
with the SHELXT structure solution program (Sheldrick, 2015a) using 
Intrinsic Phasing and refined with the SHELXL refinement package 
(Sheldrick, 2015b) using Least Squares minimisation. All non-hydrogen 
atoms were refined anisotropically. Hydrogen atoms were assigned to 
calculated positions using a riding model with appropriately fixed 
isotropic thermal parameters. Molecular graphics were generated using 
OLEX2 (Dolomanov et al., 2009). There is disorder in O15/O15a and 
C19/C20 both modelled in two positions with 88:12% occupancy. The 
disorder was modelled with restraints (SADI, SIMU, ISOR). Donor N-H 
hydrogen atoms located on the difference map and refined with re-
straints (DFIX). Crystallographic data for the structures in this paper 
have been deposited with the Cambridge Crystallographic Data Centre 
as supplementary publication no. 204963. Copies of the data can be 
obtained, free of charge, on application to CCDC, 12 Union Road, 
Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033 or e-mail:depos-
it@ccdc.cam.ac.uk). 
2.2.11. Crystal morphology of DPS 
Crystals of DPS were obtained as described in Section 2.2.10. Mi-
crographs of the crystal morphology were taken by a Q IMAGING Fast 
1394 camera (Olympus, Japan) using an Olympus BX53 polarising op-
tical microscope (Japan) equipped with a U-POT cross polarizer. 
2.2.12. Computational analysis 
Mercury 2020.3 software (UK) was used to calculate the PXRD 
powder patter of DPS based on the single-crystal X-ray structure and to 
predict the Bravais, Friedel, Donnay and Harker (BFDH) morphology of 
DPS and SEBA (CCDC code SEBAAC05 (Thalladi et al., 2000)). Mercury 
software was also used to generate full interactions map. The set of 
probes: uncharged NH, carbonyl oxygen and alcohol oxygen were used 
to provide an interaction map indicative of hydrogen bond acceptors 
(shown in red) and donors (shown in blue). Map contour levels and 
hotspots were applied to indicate how likely interactions are to occur. 
The higher the opacity of the contour, the higher the chances of 
interactions. 
3. Results and discussion 
3.1. Thermal analysis of binary physical mixtures of PRO and SEBA 
DSC thermograms for the first heating cycle of PRO, SEBA and their 
physical mixtures are shown in Fig. 2a. Thermal analysis found that the 
melting temperature of pure PRO was 91.8 ◦C, which is in a good 
agreement with the literature value of 92.9 ◦C (Neau et al., 1993). All 
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physical mixtures containing 0.67 and above mole fraction of PRO show 
similar thermal features. The first event can be attributed to the melting 
of PRO, which is then followed by an exothermic peak at around 100 ◦C 
and finally, a sharp endotherm is observed above 150 ◦C. The latter 
peak, with an onset at 166 ◦C, has the greatest enthalpy of melting 
(142.6 J/g) for the 2:1 mol/mole of PRO to SEBA. Considering that the 
melting point of SEBA is 133.5 ◦C, it can be hypothesised that the 
endotherm above 150 ◦C indicates melting of a new phase formed be-
tween PRO and SEBA. Yamashita et al. reported the appearance of an 
exothermic peak associated with cocrystal formation for 17 different 
cocrystals (Matsuoka et al., 2013). Based on the melting enthalpy values, 
it is possible that the stoichiometry of this new phase is 2 mol of PRO and 
1 mol of SEBA (0.67 mol fraction of PRO). The thermogram of the mix 
containing 0.6 mol fraction of PRO is more complex and displays a 
“split” and broad exothermal event between 100 and 110 ◦C preceded by 
the PRO melting peak. Finally, an endotherm above 150 ◦C is present 
due to melting of the new phase. The DSC curves containing 0.5 mol of 
PRO and less showed, firstly, the melting endotherm of PRO at app. 
92 ◦C followed by another endotherm appearing at a constant temper-
ature of 103 ◦C. The second peak was followed by yet another endo-
therm in case of samples comprising 0.1–0.3 PRO, however the position 
of this peak was variable and seen to appear at a lower temperature with 
an increasing content of PRO. This peak can be ascribed to melting of 
SEBA. Considering that the position of the second endothermic peak, at 
around 103 ◦C, is relativity constant and unaffected by the sample 
composition, it might indicate the formation of a eutectic phase (Diarce 
et al., 2016), however it was unclear from the DSC data what the 
composition of this eutectic might be. Nevertheless, the greatest 
enthalpy of this peak was measured for the 1:2 mol/mole PRO to SEBA 
(0.33 mol fraction of PRO) sample, which was 172.3 J/g. 
Following the first heating, the samples were quench cooled at a 
nominal cooling rate of 300 ◦C/min (Fig. S1) and subjected to the second 
heating cycle (at 10 ◦C/min). This approach was employed to examine 
the ability of samples to supercool and also to determine the magnitude 
of intermolecular forces in the disordered state (Koperwas et al., 2016; 
Umerska et al., 2020). SEBA and the samples containing 0.1–0.3 mol of 
PRO crystallised on cooling and, therefore, no glass transition temper-
atures (Tgs) were observed for these samples. The thermograms of these 
mixtures displayed an endotherm, most likely of the crystallised SEBA 
(Fig. 2b). All other samples showed Tgs (Fig. S2) and the compositional 
relationship of the Tg values is presented in Fig. 3a. Interestingly, the 
mixture containing 0.67 mol of PRO had the highest Tg of 22 ◦C, which 
indicates that the intermolecular forces were the strongest at this 
composition (Umerska et al., 2020; Zotova et al., 2020). On the other 
hand, the sample comprising 0.33 PRO, which in the first heating 
showed the greatest enthalpy of the eutectic-like peak, had the lowest 
Tg, − 25 ◦C, suggesting weakly interacting molecules (Wojnarowska 
et al., 2019; 2018). Crystallisation on the second heating cycle was 
detected for samples containing more than 0.5 mol fraction of PRO with 
the samples comprising 0.33–0.5 mol fraction of PRO showing excellent 
thermal stability on reheating (Fig. 2b). Again, the endothermal peak at 
around 166 ◦C for the 2:1 mol/mole PRO to SEBA was the one that was 
the most pronounced, therefore the crystallisation exotherm can be 
ascribed, at least in part, to crystallisation of this new phase. As 
compared to the first heating cycle the melting of PRO was only 
observed for samples at 0.9 and 0.8 mol fraction of PRO supporting the 
above suggestion that PRO is involved in formation of the new multi-
component phases. 
As alluded to above, the DSC data suggested that the eutectic phase 
comprises around 0.33 mol of PRO as at this composition a single, sharp 
endotherm was produced, which also had the greatest enthalpy. How-
ever, one cannot simply determine the exact eutectic composition 
directly from DSC profiles, as eutectic phases do not always form in 
stoichiometric ratios (Cherukuvada and Nangia, 2014). The composition 
of a eutectic phase can accurately be confirmed by the construction of a 
Tammann plot (Fiandaca et al., 2020; Umerska et al., 2020). Thus, the 
enthalpy values of the eutectic endotherm assumed to be of a eutectic 
obtained from the first heating cycle were plotted against the mole 
fraction of PRO to obtain a triangular Tammann plot (Fig. 3b). Two lines 
are determined as best linear fits of the points and the eutectic compo-
sition is exactly at the intersection of these two lines giving the plot a 
triangular shape (Évora et al., 2016; Meltzer and Pincu, 2012). The 
eutectic composition, at 0.33 mol fraction of PRO, based on the Tam-
mann plot agreed with that as determined directly from the DSC traces. 
3.2. Identification of phases 
Thermal analysis studies presented above suggested that two new, 
possibly multicomponent, phases might have formed during heating of 
PRO/SEBA physical mixtures, one which had a higher melting point 
Fig. 2. Thermal analysis of binary physical mixtures of PRO and SEBA: a) DSC traces of PRO/SEBA physical mixtures from the first heating cycle, b) DSC traces of 
PRO/SEBA physical mixtures from the second heating cycle. The labels represent the mole fraction of PRO. 
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than either PRO or SEBA and the other one was most likely to be a 
eutectic. Further analysis was performed to clarify the identity and 
composition of these phases. 
The diffractograms of freshly prepared mechanical mixtures of PRO 
and SEBA showed peaks of the starting components (Fig. S3). However, 
the thermally treated samples (Fig. 4a) evidently show new peaks of a 
new phase. PXRD of the mixture at 0.67 mol fraction of PRO shows a 
distinctly different diffraction pattern with a characteristic peak at 6◦ 2θ 
in addition to other reflections in the diffractogram that cannot be 
assigned to any of the starting materials. The PXRD pattern of the heated 
mixture at 0.33 mol fraction of PRO, showed the presence of peaks that 
could be assigned to the new phase (6◦ and 16◦ 2θ) and SEBA (8◦, 22◦
and 24◦ 2θ). The absence of peaks characteristic of PRO evidences that 
PRO does not seem to be directly involved in the formation of the 
eutectic. It can be concluded that the phase visible in the thermograms at 
around 103 ◦C is indeed a eutectic, but it is composed of SEBA and the 
new phase that melts at 166 ◦C. 
FTIR analysis enabled further investigations into the nature of the 
interactions between PRO and SEBA. As highlighted in Introduction, 
there is a possibility of ionic interactions occurring between these two 
components due to ionisable carboxylic groups present on SEBA and a 
basic secondary amine group, which may act as a proton acceptor, on 
PRO. The FTIR spectra of the heat-treated mixtures are shown in Fig. 4b. 
The spectrum of SEBA shows a characteristic absorption of the carbonyl 
group due to the presence of protonated carboxylic acid groups at 1687 
cm− 1 (Sailakshmi et al., 2012). The band is the broadest for pure acid 
due to the presence of strong intermolecular hydrogen bonding. In-
tensity of this peak decreases with an increase of PRO until it disappears 
completely when the PRO content increases to 0.7 mol fraction. At the 
same time, as the amount of PRO in the binary mixtures increases, new 
peaks at 1564 cm− 1 and 1389 cm− 1 appear corresponding to the 
asymmetric and symmetric vibrations of the carboxylate anion, 
respectively. These peaks have the highest intensity at 0.67 mol fraction 
of PRO. Therefore, it may be concluded that the 2:1 mol/mole PRO/ 
SEBA composition (0.67 mol of PRO) forms a salt upon heating. The 
spectrum of system comprising 0.33 mol fraction PRO showed peaks 
characteristic of the salt and of SEBA, supporting the premise of a 
eutectic phase and discounting possibility of another salt. 
Fig. 3. a) Glass transition (Tg)-composition relationships for supercooled PRO/SEBA and DPS/SEBA mixtures. The lines are a guide for the eye. b) Tammann plots 
constructed using thermal data obtained from the first heating of physical mixtures (PRO/SEBA and DPS/SEBA). The lines are best fits to the data points. 
Fig. 4. a) PXRD patterns and b) FT-IR spectra of PRO and SEBA “as received” powders as well as PRO/SEBA physical mixtures subjected to thermal pre-treatment. 
The labels represent the mole fraction of PRO. The PRO/SEBA samples containing 0.1–0.5 mol fraction of PRO were heated to 100 ◦C, cooled to room temperature 
and then analysed. The PRO/SEBA samples containing 0.6–0.9 mol fraction of PRO were heated to 120 ◦C, cooled to room temperature and then analysed. The stars 
indicate characteristic peaks of SEBA, exclamation signs – PRO and arrows – DPS. 
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Based on the results of thermal analysis, PXRD and FTIR, a full phase 
diagram was constructed and the phases, as identified, are presented in 
Fig. 5. At higher contents of PRO, the melt of PRO facilitates the 
dissolution of SEBA and the phase, salt, crystallises as seen previously for 
e.g. ciprofloxacin succinate (Paluch et al., 2013). However, the eutectic 
phase, melting at around 100 ◦C and seen to form at lower PRO contents, 
appears to facilitate the solid-state reaction to the salt as the sharp 
exothermal event can no longer be observed, nevertheless the eutectic is 
composed of the salt and SEBA. 
3.3. Crystallographic analysis of the salt 
The salt was recrystallised from ethanol for the structure elucidation. 
To confirm its purity DSC analysis was performed. It was found that the 
onset of melting of pure salt is 169.5 ◦C and the enthalpy of this process 
is 178.2 J/g. TGA analysis of the salt revealed that it is thermally stable 
up to the melting point (170 ◦C) showing a weight loss of 1.3%. The 
weight loss up to 180 ◦C was 4.4%. 
The structure of the new salt, dipropranolol sebacate (DPS), was 
determined by SCXRD and is shown in Fig. 6. The molecule crystallises 
in the centrosymmetric space group P1, indicating the salt is racemic 
(Table S1). The asymmetric unit contains one molecule of the PRO 
cation and a half a molecule of SEBA, and the complete molecule is 
generated by symmetry in the ratio of 2:1 PRO/SEBA. There is disorder 
in the terminal isopropyl carbons (C19, C20) and in the hydroxyl O15/ 
H14 positions (Fig. S4). In the major disordered moiety, each PRO cation 
is hydrogen bonded to the SEBA dianion via the protonated amine 
(asymmetric bifurcated N17…O21, 3.4084(16) Å; N17…O22, 2.7430 
(16) Å) as well as the hydroxyl group (asymmetric bifurcated O15… 
O21, 2.6729(16) Å; O15…O22, 3.3171(18) Å). The minor disordered 
moiety displays a similar pattern, but with different hydrogen bond 
lengths from O15a…O21, 2.910(13) Å (Fig. S5). Further stabilisation by 
hydrogen bonding is seen via the amino N17 to a neighbouring SEBA 
oxygen N17…O21iii, 2.7630(16) Å (symmetry generation iii = 2-x, 1-y, 
1-z) and weaker CH…O interactions (C20…O22, 3.304(7) Å; C13… 
O22ii, 3.2362(19) Å; symmetry generation ii = 1-x, 1-y, 1-z) also assist 
the structure stabilisation and connect the structure into a 3D network 
(Fig. S5). A calculated PXRD pattern, generated from the data above is 
shown in Fig. S6. The fit is visually reasonable and a Le Bail refinement 
yields Rp = 92.9% and Rwp = 90.1%. The predicted morphology based 
on the structure of DPS is also shown in Fig. 6b. It was found that 
experimental morphology matches the predicted triclinic structure as 
shown in Fig. 6c. 
3.4. Solvent-free formation of DPS 
Since solvent-free approaches to the formation of multicomponent 
systems are preferred (Évora et al., 2019; Mottillo and Frǐsčić, 2017; 
Zotova et al., 2020), upon establishing that the salt forms upon heating 
of the starting components (PRO and SEBA) to app. 105 ◦C (Fig. 2), an 
experiment was designed to investigate if it is possible for DPS to form 
without an excessive input of thermal energy. Two tests were carried 
out, one involving very gentle mixing (contact method) of PRO with 
SEBA in a 2:1 M ratio and the other was a grinding-assisted method. The 
samples were then stored at 25 and 60 ◦C and the reaction monitored by 
PXRD. 
In relation to the contact method, there was no evidence of the salt 
formation after 14 days for the sample stored at 25 ◦C. Whereas a weak 
diffraction peak at 6◦ 2θ, unique to DPS, was observed after 14 days for 
the powder mixture stored at 60 ◦C (Fig. 7a). Considering the ground 
samples, the salt formation was seen after 7 days of storage at 25 and 
60 ◦C (Fig. 7b). According to Paul and Curtin solid state reactions occur 
in four stages: 1) loosening of molecules at the reaction site; 2) molec-
ular change; 3) solid solution formation and 4) separation of the product 
(Paul and Curtin, 1973). Step 1) is critical for the reaction to occur as it 
often requires an energy input. When the powders were just gently 
mixed with the spatula, the was no additional loosening of molecules 
from the surface and it is likely that crystal imperfections (defects) 
present on the “as supplied” samples were the only source of molecules 
available for the reaction. Molecular mobility was accelerated by 
applying the 60 ◦C thermal storage. The loosening of molecules at the 
reaction site can be greatly facilitated by grinding as mechanical forces 
are used (Takacs, 2014). As it is expected that the reaction rate is slow, 
no salt was observed immediately after grinding, however upon storage 
an appreciable level of conversion to the salt had occurred, enough for 
the PXRD to detect the new phase. 
The formation of DPS at 25 and 60 ◦C is somewhat surprising, but it 
can be explained by the presence of crystal imperfections and/or dis-
order induced by grinding. For the fast conversion to the salt, melting of 
PRO (at around 90 ◦C) is still required, as shown in Fig. 2a, with the drug 
in the liquid state enabling dissolution of SEBA, the proton transfer 
between the species and then release of excess energy during the crystal 
formation, thus following the 4 stages of a solid state reaction described 
above. This can be simply carried out in an oven, however the possibility 
of a shear-induced disorder facilitating a further mobility of molecules at 
the contact sites, shown here on a small scale, may suggest that a fast 
conversion to the salt at larger scale can be achieved by e.g. hot melt 
extrusion, a technique combining the heat treatment coupled with the 
shear-induced disorder instigated by the moving screws (Lee et al., 
2017). In relation to obtaining a crystalline product, the salt crystal-
lisation process does not depend on the heating rate (Fig. S7), making 
the process easier to predict and control. Furthermore, as elucidated in 
Section 3.2, at low PRO contents, processing could be carried out in the 
eutectic melting zone, thus lowering the energy input even further. 
3.5. DPS/SEBA interactions and physicochemical properties of the 
eutectic phase 
Eutectics belong to a class of low-melting multicomponent crystal-
line solids (Cherukuvada and Nangia, 2014). The eutectic phase for-
mation has been found as a useful strategy in improving solubility of 
APIs (Figueirêdo et al., 2017). It has been also successfully used to 
improve skin permeation of several APIs such as lidocaine/ prilocaine 
(Friedman et al., 2001) and ibuprofen (Stott et al., 1998). A eutectic may 
form if there are cohesive and non-covalent interactions between dis-
similar components (Cherukuvada and Nangia, 2014). The existence 
and formation of a eutectic between compounds can be confirmed by 
Fig. 5. Temperature/composition phase diagram for the PRO/SEBA system. 
Solid datapoints are based on first DSC heating of PRO/SEBA physical mixtures, 
while the open datapoints are based on first DSC heating of DPS/SEBA physical 
mixtures. The broken lines are a guide for the eye. 
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constructing a phase diagram. There are two types of commonly rec-
ognised binary phase diagrams, which represent the eutectic formation. 
They may be either V- or W-shaped (Cherukuvada, 2016). The first 
involves formation of a eutectic between an acid and a base only, 
whereas the latter involves formation of a cocrystal (a new phase). The 
new phase then forms a eutectic either with a pure acid and/or a base. 
Fig. 6. a) Symmetry generated structure of DPS 
(symmetry transformation used to generate 
equivalent atoms i = 1-x, 1-y, -z) with atomic 
displacement shown at 50% probability and only 
hydrogen atoms involved in hydrogen bonding 
shown for clarity. Dotted lines indicate hydrogen 
bonding. Only the majority occupied (88%) 
disordered moiety is shown. b) Bravais, Friedel, 
Donnay and Harker (BFDH) predicted crystal 
morphology based on the SCXRD structure of 
DPS. c) Experimental morphology of DPS 
crystals.   
Fig. 7. a) PXRD of PRO/SEBA (2:1) samples prepared by prepared by gentle mixing with a spatula (contact method) and stored at 25 and 60 ◦C; b) PXRD of PRO/ 
SEBA (2:1) samples prepared by prepared by grinding in a mortar and pestle (grinding-assisted method) and stored at 25 and 60 ◦C. Stars indicate the characteristic 
peaks of DPS. 
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There are only a few phase diagrams reported, which involve the salt 
formation and then that salt forming a eutectic (Cooke et al., 2010; Stott 
et al., 2001). Therefore, it appears that the DPS forming a eutectic sys-
tem with SEBA belongs to this uncommon group of multicomponent 
pharmaceutical systems. The association of the salt into the eutectic 
allows to decrease of the melting point by nearly 70 ◦C, which may be 
advantageous for downstream processing. 
Detailed thermal analysis of DPS/SEBA physical mixtures was con-
ducted to understand the differences in behaviour between the compo-
nents, especially the eutectic, when the in situ salt formation was 
eliminated. DSC thermograms (Figs. S8 and S9) confirmed that PRO 
does not directly partake in the formation of eutectic. As stated in Sec-
tion 3.1, the eutectic composition determined from the Tammann plot 
based on the PRO/SEBA physical mixtures comprises 0.33 mol fraction 
of PRO, consistent with the data obtained using the DPS/SEBA systems 
(Fig. 3b). However, the enthalpies of the eutectic phase, as determined 
form the Tammann plots, were different, 161 J/g versus 120 J/g for the 
PRO/SEBA and DPS/SEBA mixtures, respectively. It may be explained 
by a better solubility or miscibility of components (DPS and SEBA) when 
the source of PRO was the salt itself, with no energy utilised for the in situ 
salt formation. The enthalpy difference can also be attributed to the 
presence of weak intermolecular forces between the components leading 
to cluster formation (Rastogi et al., 1981; Umerska et al., 2020). The Tg 
versus composition plot for the supercooled DPS/SEBA mixtures 
(Fig. 3a) showed that the samples containing below 0.4 mol fraction of 
PRO crystallised on cooling, therefore, no Tg was observed for these 
samples. However, unlike for the supercooled PRO/SEBA physical 
mixtures, no Tg was observed for the sample comprising 0.33 mol 
fraction of PRO which represents the eutectic. The overall trend of Tg 
versus PRO content was very similar with the Tg values decreasing as the 
composition of the eutectic was approached. 
To elucidate the nature of interactions between the phases forming 
the eutectic, DPS and SEBA, a detailed infrared analysis was performed 
(Fig. 8a). Pronounced differences can be noticed associated with the 
SEBA vibrational groups (Max and Chapados, 2004; Sailakshmi et al., 
2012). The broad band at 1687 cm− 1 of pure SEBA, indicative of some 
dimer presence, is slightly shifted to higher wavenumbers in the eutectic 
(1694 cm− 1), this band is also narrower in comparison to that of pure 
SEBA. This strongly suggests H-bond rearrangement in the acid and a 
possibility of interaction with the salt. Notable changes are seen in the 
bands associated with the –OH moiety, demonstrated as shifts and 
narrowing of bending vibrations, in plane and out of plane (around 
1410–1430 cm− 1 and 920 cm− 1, respectively) of SEBA in the eutectic, 
suggestive of H-bond type interactions between the acid and DPS at the 
inter-phase, already suggested by the thermal analysis. Fig. 8b show the 
multicomponent microstructure of the eutectic made of multiple do-
mains facilitating intimate contact between DPS and SEBA. 
Since the eutectic microstructure is composed of domains of solid 
solutions held together by weak inter-phase boundaries (Fig. 8b) and the 
lattice structures of parent components remain principally unaffected 
(Cherukuvada and Nangia, 2014), a simulation was conducted using the 
BFDH representation of DPS and SEBA crystal morphologies and the full 
interaction map option to visualise the interaction sites (Mugheirbi and 
Tajber, 2015; Wood et al., 2013). The interaction map shows a possible 
interaction with hydrogen bond acceptors as red hot spots and possible 
interactions with hydrogen bond donors as blue hot spots. The higher 
the opacity of the contour, the greater the chance of the investigated 
interaction to take place (Wood et al., 2013). Inspecting the interaction 
map of a single SEBA molecule, it can be concluded that it can act as a H- 
bond donor and/or acceptor (Fig. 9a). The salt, due to the presence of 
several chemical groups can also interact with both H-bond acceptors 
and H-bond donors (Fig. 9b). BFDH predictions enable the surface area 
of key crystallographic faces to be determined. This information coupled 
with the interaction maps created for the BFDH crystal morphologies 
show that the principal interacting faces in the eutectic might be (100) 
and (100) of SEBA (52% surface area) as well as (001) and (001) of DPS 
(45% surface area) (Fig. 9 c and d) as the interacting parts of the com-
pounds will be exposed at those faces. Assuming hypothetically that in 
the eutectic the only interacting surfaces will be those primary faces, the 
theoretical composition of such a eutectic would be 0.63 mol fraction of 
SEBA and 0.37 mol fraction of PRO, which is very close to the experi-
mental value of 0.33 mol fraction of PRO. Concluding, crystallographic 
analysis, like this presented here, can be helpful in understanding in-
teractions at the inter-phase between components of a eutectic. To the 
best of our knowledge, BFDH/full interaction maps analysis has never 
been used for such a purpose. 
4. Conclusions 
This research was undertaken to comprehensively demonstrate the 
nature of interactions occurring between PRO and SEBA in the various 
solid-state phases. A binary phase diagram was successfully applied to 
prove the existence of two new forms of PRO: a salt (at 0.67 mol of PRO, 
dipropranolol sebacate) and a eutectic form (at 0.33 mol of PRO). It was 
shown that there is a possibility of in situ salt formation while thermally 
treating a physical mixture of PRO and SEBA, confirming that the heat- 
induced and solvent-free crystallisation of the salt is a viable route of 
manufacturing. Investigations into the mechanisms of the salt formation 
Fig. 8. a) FTIR spectra of SEBA, DPS and the eutectic phase. ν – stretching 
vibration, δ – bending vibration, ω – wagging vibration, ip – in plane, oop – out 
of plane. b) Polarised light microscopy of the eutectic at 25 ◦C. 
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showed that dipropranolol sebacate (DPS) can be obtained by mecha-
nochemical means such as grinding as well as by crystallisation from 
solution. The crystal structure of the salt was solved, ultimately con-
firming ionisation between PRO and SEBA and the salt stoichiometry. 
DPS was found to interact via H-bond type interactions with SEBA to 
form a eutectic phase. The enthalpy of melting of the eutectic was used 
to generate a Tammann plot, which gave the exact composition of this 
phase (0.33 mol of PRO). Experimental analysis (infrared spectroscopy) 
and simulated data (BFDH crystal morphology coupled with full inter-
action maps) allowed to further understand the nature of interactions 
which led to the formation of the eutectic phase. 
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Évora, A.O.L., Castro, R.A.E., Maria, T.M.R., Ramos Silva, M., Canotilho, J., Eusébio, M. 
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